Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate
Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate
nurix therapeutics 2024年Q2 GAAP每股收益$(0.71)，未达$(0.63)的预期，销售额为1209.2万美元，未达到2210.5万美元的预期
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.63) by 12.7 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $12.092 million which missed the analyst consensus estimate of $22.105 million by 45.30 percent. This is a 60.58 percent decrease over sales of $30.676 million the same period last year.
Nurix Therapeutics（纳斯达克股票代码：NRIX）报告季度每股亏损0.71美元，比分析师预估的每股亏损0.63美元低12.7％。相对去年同期每股亏损0.45美元，该数字下降了57.78％。公司报告了1209.2万美元的季度销售额，相比分析师预估的2210.5万美元低了45.30％。这是去年同期销售额3067.6万美元的下降了60.58％。